{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:38:06Z","timestamp":1771511886381,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03971-y","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T06:48:59Z","timestamp":1766472539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenomic, pharmacokinetic, and safety analysis of CYP3A4\/CYP3A5 polymorphisms of midostaurin in patients with acute myeloid leukemia"],"prefix":"10.1007","volume":"82","author":[{"given":"Romain","family":"Sechaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Rahmanzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal Krishna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Guichard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans D.","family":"Menssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"4","key":"3971_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"issue":"2","key":"3971_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3109\/10428194.2013.800198","volume":"55","author":"S Kayser","year":"2014","unstructured":"Kayser S, Levis MJ (2014) FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. Leuk Lymphoma 55(2):243\u2013255. https:\/\/doi.org\/10.3109\/10428194.2013.800198","journal-title":"Leuk Lymphoma"},{"key":"3971_CR3","unstructured":"EMA (2022) Rydapt\u00ae (midostaurin) capsules. Accessed 20 February 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rydapt#product-information-section"},{"key":"3971_CR4","unstructured":"RYDAPT\u00ae(midostaurin) capsules, for oral use (2017) Initial U.S. Approval: 2017. Accessed 9 September 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207997s008lbledt.pdf"},{"issue":"38","key":"3971_CR5","doi-asserted-by":"publisher","first-page":"5576","DOI":"10.1021\/acs.biochem.8b00727","volume":"57","author":"PW Manley","year":"2018","unstructured":"Manley PW, Caravatti G, Furet P, Roesel J, Tran P, Wagner T, Wartmann M (2018) Comparison of the kinase profile of midostaurin (Rydapt) with that of its predominant metabolites and the potential relevance of some newly identified targets to leukemia therapy. Biochemistry 57(38):5576\u20135590. https:\/\/doi.org\/10.1021\/acs.biochem.8b00727","journal-title":"Biochemistry"},{"issue":"5","key":"3971_CR6","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.116.072744","volume":"45","author":"H He","year":"2017","unstructured":"He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, Heimbach T (2017) Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism, and excretion studies of a BDDCS II drug. Drug Metab Dispos 45(5):540\u2013555. https:\/\/doi.org\/10.1124\/dmd.116.072744","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"3971_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.dmd.2025.100036","volume":"53","author":"H Gu","year":"2025","unstructured":"Gu H, Sechaud R, Hanna I, Pelis R, Einolf HJ (2025) Physiologically based pharmacokinetic modeling of midostaurin and metabolites at steady-state to bridge drug interaction scenarios in lieu of clinical trials. Drug Metab Dispos 53(3):100036. https:\/\/doi.org\/10.1016\/j.dmd.2025.100036","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"3971_CR8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00280-022-04448-w","volume":"90","author":"R Sechaud","year":"2022","unstructured":"Sechaud R, Sinclair K, Grosch K, Ouatas T, Pathak D (2022) Evaluation of drug-drug interactions between midostaurin and strong CYP3A4 inhibitors in patients with FLT-3-mutated acute myeloid leukemia (AML). Cancer Chemother Pharmacol 90(1):19\u201327. https:\/\/doi.org\/10.1007\/s00280-022-04448-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"3971_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-023-04635-3","author":"R Sechaud","year":"2024","unstructured":"Sechaud R, Gu H, Rahmanzadeh G, Taylor A, Chiparus O, Sharma GK, Breitschaft A, Menssen HD (2024) Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants. Cancer Chemother Pharmacol. https:\/\/doi.org\/10.1007\/s00280-023-04635-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"3971_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00280-024-04683-3","volume":"94","author":"R Sechaud","year":"2024","unstructured":"Sechaud R, Gu H, Rahmanzadeh G, Chiparus O, Breitschaft A, Menssen HD (2024) Effect of midostaurin on the pharmacokinetics of P-gp, BCRP, and CYP2D6 substrates: assessing potential drug-drug interactions in healthy participants: brief title: Drug-drug interaction of midostaurin. Cancer Chemother Pharmacol 94(4):535\u2013547. https:\/\/doi.org\/10.1007\/s00280-024-04683-3","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"3971_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/dmd.31.7.815","volume":"31","author":"TD Bjornsson","year":"2003","unstructured":"Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA, Pharmaceutical R, Manufacturers of America Drug Metabolism\/Clinical Pharmacology (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815\u2013832 Technical Working G, Evaluation FDACfD, Research. https:\/\/doi.org\/10.1124\/dmd.31.7.815","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"3971_CR12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/cpt.1834","volume":"108","author":"M Maliepaard","year":"2020","unstructured":"Maliepaard M, Toiviainen T, De Bruin ML, Meulendijks D (2020) Pharmacogenetic-pharmacokinetic interactions in drug marketing authorization applications via the European Medicines Agency between 2014 and 2017. Clin Pharmacol Ther 108(2):338\u2013349. https:\/\/doi.org\/10.1002\/cpt.1834","journal-title":"Clin Pharmacol Ther"},{"key":"3971_CR13","unstructured":"CYP3A4. Accessed 10 October 2023. https:\/\/www.pharmvar.org\/gene\/CYP3A4"},{"key":"3971_CR14","unstructured":"CYP3A5. Accessed 11 October 2023. https:\/\/www.pharmvar.org\/gene\/CYP3A5"},{"issue":"3","key":"3971_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/clpt.2014.129","volume":"96","author":"AN Werk","year":"2014","unstructured":"Werk AN, Cascorbi I (2014) Functional gene variants of CYP3A4. Clin Pharmacol Ther 96(3):340\u2013348. https:\/\/doi.org\/10.1038\/clpt.2014.129","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3971_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40262-018-0719-5","volume":"58","author":"S Bins","year":"2019","unstructured":"Bins S, Huitema ADR, Laven P, Bouazzaoui SE, Yu H, van Erp N, van Herpen C, Hamberg P, Gelderblom H, Steeghs N, Sleijfer S, van Schaik RHN, Mathijssen RHJ, Koolen SLW (2019) Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. Clin Pharmacokinet 58(5):651\u2013658. https:\/\/doi.org\/10.1007\/s40262-018-0719-5","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3971_CR17","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1038\/s41598-019-41820-y","volume":"9","author":"T Ozeki","year":"2019","unstructured":"Ozeki T, Nagahama M, Fujita K, Suzuki A, Sugino K, Ito K, Miura M (2019) Influence of CYP3A4\/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer. Sci Rep 9(1):5404. https:\/\/doi.org\/10.1038\/s41598-019-41820-y","journal-title":"Sci Rep"},{"key":"3971_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.711943","volume":"12","author":"TAM Mulder","year":"2021","unstructured":"Mulder TAM, van Eerden RAG, de With M, Elens L, Hesselink DA, Matic M, Bins S, Mathijssen RHJ, van Schaik RHN (2021) CYP3A4( *)22 genotyping in clinical practice: ready for implementation? Front Genet 12:711943. https:\/\/doi.org\/10.3389\/fgene.2021.711943","journal-title":"Front Genet"},{"issue":"8\u20139","key":"3971_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/bdd.732","volume":"31","author":"ZE Barter","year":"2010","unstructured":"Barter ZE, Perrett HF, Yeo KR, Allorge D, Lennard MS, Rostami-Hodjegan A (2010) Determination of a quantitative relationship between hepatic CYP3A5*1\/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharm Drug Dispos 31(8\u20139):516\u2013532. https:\/\/doi.org\/10.1002\/bdd.732","journal-title":"Biopharm Drug Dispos"},{"issue":"28","key":"3971_CR20","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","volume":"28","author":"T Fischer","year":"2010","unstructured":"Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ (2010) Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28(28):4339\u20134345. https:\/\/doi.org\/10.1200\/JCO.2010.28.9678","journal-title":"J Clin Oncol"},{"issue":"5","key":"3971_CR21","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/s1535-6108(02)00069-7","volume":"1","author":"E Weisberg","year":"2002","unstructured":"Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD (2002) Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 1(5):433\u2013443. https:\/\/doi.org\/10.1016\/s1535-6108(02)00069-7","journal-title":"Cancer Cell"},{"key":"3971_CR22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148129","author":"JJ Cloos","year":"2021","unstructured":"Cloos JJ, Montesinos P, Fiedler W, M\u00fcller R, Krauter J, Sica S, Westermann J, Heidinga ME, Ngai LL, Oussoren-Brockhoff YJM, D\u00f6hner H, Levis M, Ossenkoppele GJ, Stone RM, Koenen G, Bengoudifa BR, Cheng Y, Medts T, Heidinger V, Sachs C, Sierra J (2021) Midostaurin in patients (Pts) with newly diagnosed FLT3-mutation negative acute myeloid leukemia (AML): final results and measurable residual disease (MRD) analyses from the Unify Trial. Blood. https:\/\/doi.org\/10.1182\/blood-2021-148129","journal-title":"Blood"},{"issue":"1","key":"3971_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/dmpt-2016-0024","volume":"32","author":"L Ganoci","year":"2017","unstructured":"Ganoci L, Bozina T, Mirosevic Skvrce N, Lovric M, Mas P, Bozina N (2017) Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metab Pers Ther 32(1):11\u201321. https:\/\/doi.org\/10.1515\/dmpt-2016-0024","journal-title":"Drug Metab Pers Ther"},{"issue":"1","key":"3971_CR24","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"UM Zanger","year":"2013","unstructured":"Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138(1):103\u2013141. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.12.007","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3971_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","volume":"12","author":"JK Lamba","year":"2002","unstructured":"Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12(2):121\u2013132. https:\/\/doi.org\/10.1097\/00008571-200203000-00006","journal-title":"Pharmacogenetics"},{"issue":"3","key":"3971_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/phgs.5.3.243.29833","volume":"5","author":"HG Xie","year":"2004","unstructured":"Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR (2004) Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5(3):243\u2013272. https:\/\/doi.org\/10.1517\/phgs.5.3.243.29833","journal-title":"Pharmacogenomics"},{"issue":"4","key":"3971_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383\u2013391. https:\/\/doi.org\/10.1038\/86882","journal-title":"Nat Genet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03971-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03971-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:36Z","timestamp":1771508376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03971-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3971"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03971-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies were performed in accordance with ethical principles, which have their origin in the Declaration of Helsinki, and are consistent with Good Clinical Practice and applicable regulatory requirements. All participants of the study provided written informed consent according to international standards. The study was registered under EudraCT number: 2017-003540-21, and it obtained a favorable opinion from the IEC. The study participants were informed about the study procedures, risks, and benefits of their participation. Informed consent was documented by the investigator.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and informed consent"}},{"value":"R Sechaud, T Peters, N Guichard, G Rahmanzadeh, and H Menssen are employees of Novartis Pharma AG, Switzerland and may hold shares. H Gu is an employee of Novartis Pharmaceuticals Corporation, USA and may hold shares. G K Sharma is an employee of Novartis Healthcare Pvt. Ltd., India and may hold shares.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19"}}